Bayesian estimation of cost-effectiveness ratios from clinical trials

被引:0
|
作者
Heitjan, DF
Moskowitz, AJ
Whang, W
机构
[1] Columbia Univ, Joseph L Mailman Sch Publ Hlth, Div Biostat, New York, NY 10032 USA
[2] Columbia Univ, Int Ctr Hlth Outcomes & Innovat Res, New York, NY 10032 USA
关键词
Bayesian inference; clinical trials; confidence intervals; cost-effectiveness ratios; net health benefit;
D O I
10.1002/(SICI)1099-1050(199905)8:3<191::AID-HEC409>3.0.CO;2-R
中图分类号
F [经济];
学科分类号
02 ;
摘要
Estimation of the incremental cost-effectiveness ratio (ICER) is difficult for several reasons: treatments that decrease both cost and effectiveness and treatments that increase both cost and effectiveness can yield identical values of the ICER; the ICER is a discontinuous function of the mean difference in effectiveness; and the standard estimate of the ICER is a ratio. To address these difficulties, we have developed a Bayesian methodology that involves computing posterior probabilities for the four quadrants and separate interval estimates of ICER for the quadrants of interest. We compute these quantities by simulating draws from the posterior distribution of the cost and effectiveness parameters and tabulating the appropriate posterior probabilities and quantiles. We demonstrate the method by re-analysing three previously published clinical trials. Copyright (C) 1999 John Wiley & Sons, Ltd.
引用
收藏
页码:191 / 201
页数:11
相关论文
共 50 条